Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799195 | 0.81 | MAPT (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL12344428 | 0.78 | ALDH1A1 (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL769313 | 0.78 | NPC1 (0.54) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL8221474 | 0.78 | NPC1 (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL10044923 | 0.78 | KDM4E (0.48) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL9235547 | 0.77 | NPC1 (0.50) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL11540786 | 0.77 | ALDH1A1 (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL11540789 | 0.77 | ALDH1A1 (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL14682173 | 0.77 | ALDH1A1 (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 | |
| SCHEMBL20205919 | 0.74 | MAPT (0.46) | RAB9AMAPTNPC1ALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | RAB9A 3931/4885MAPT 4533/4885NPC1 770/4885 |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | RAB9A 4632/4885MAPT 4388/4885NPC1 657/4885 |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | RAB9A 4632/4885MAPT 4388/4885NPC1 657/4885 |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | HCCS, HPN, CYP3A4 | RAB9A 4325/4885MAPT 4456/4885NPC1 563/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | RAB9A 4072/4885MAPT 3507/4885NPC1 1161/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | RAB9A 3931/4885MAPT 4533/4885NPC1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.